{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:08:27Z","timestamp":1787065707504,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903181"],"award-info":[{"award-number":["81903181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.intimp.2023.110973","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:51:02Z","timestamp":1695732662000},"page":"110973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PB","title":["Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-7618","authenticated-orcid":false,"given":"Zeming","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaotiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-4334","authenticated-orcid":false,"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2020","key":"10.1016\/j.intimp.2023.110973_b0005","first-page":"692","article-title":"Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study","volume":"147","author":"Wu","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110973_b0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"2021","key":"10.1016\/j.intimp.2023.110973_b0015","first-page":"1049","article-title":"Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015","volume":"34","author":"Bian","year":"2004","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2023.110973_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2023.110973_b0025","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cam4.2110","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2023.110973_b0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/CMR.0000000000000332","article-title":"Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors","volume":"27","author":"Tas","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.intimp.2023.110973_b0035","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, et al., Cancer statistics, 2020, CA: a cancer journal for clinicians, 70 (2020) 7-30.doi:10.3322\/caac.21590.","DOI":"10.3322\/caac.21590"},{"key":"10.1016\/j.intimp.2023.110973_b0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110973_b0045","first-page":"643","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, The Lancet","volume":"22","author":"Eggermont","year":"2021","journal-title":"Oncology"},{"issue":"2021","key":"10.1016\/j.intimp.2023.110973_b0050","first-page":"225","article-title":"Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma, European journal of cancer (Oxford","volume":"158","author":"Weber","year":"1990","journal-title":"England"},{"key":"10.1016\/j.intimp.2023.110973_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-020-07538-1","article-title":"Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis","volume":"21","author":"Toor","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2023.110973_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted Therapy and Immunotherapy for Melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.intimp.2023.110973_b0065","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110973_b0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2017.11.011","article-title":"Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor","volume":"89","author":"Yan","year":"2018","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.intimp.2023.110973_b0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.110973_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002273","article-title":"Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma","volume":"9","author":"Lynch","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.110973_b0085","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110973_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","author":"Tang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2023.110973_b0095","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.110973_b0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110973_b0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110973_b0110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41467-022-28566-4","article-title":"Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis","volume":"13","author":"Farshidfar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110973_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.intimp.2023.110973_b0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.intimp.2023.110973_b0125","unstructured":"M. Carlson, KEGG.db: A set of annotation maps for KEGG, (2019)."},{"key":"10.1016\/j.intimp.2023.110973_b0130","unstructured":"H.K.a.R.G.V. Kosuke Yoshihara, estimate: Estimate of Stromal and Immune Cells in Malignant Tumor Tissues from Expression Data, (2016)."},{"key":"10.1016\/j.intimp.2023.110973_b0135","unstructured":"A.d.R. Etienne Becht, Florent Petitprez, MCPcounter: Estimating tissue-infiltrating immune and other stromal subpopulations abundances using gene expression, (2020)."},{"key":"10.1016\/j.intimp.2023.110973_b0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2023.110973_b0145","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110973_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.intimp.2023.110973_b0155","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined Blockade of IL6 and PD-1\/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.110973_b0160","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2023.110973_b0165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.intimp.2023.110973_b0170","doi-asserted-by":"crossref","first-page":"e15067","DOI":"10.1111\/dth.15067","article-title":"Adjuvant PD-1 inhibitor versus high-dose interferon \u03b1-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis","volume":"34","author":"Li","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2023.110973_b0175","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ejca.2011.03.019","article-title":"A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon \u03b1-2b in high-risk acral melanoma patients","volume":"47","author":"Mao","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110973_b0180","first-page":"1198","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients, Annals of oncology : official journal of the European Society for","volume":"31","author":"Nakamura","year":"2020","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2023.110973_b0185","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaad.2019.09.029","article-title":"Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations","volume":"83","author":"Oh","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110973_b0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1203475418800943","article-title":"Acral Lentiginous Melanoma: Survival Analysis of 715 Cases","volume":"23","author":"Lino-Silva","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.intimp.2023.110973_b0195","doi-asserted-by":"crossref","first-page":"1090737","DOI":"10.3389\/fmed.2023.1090737","article-title":"Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis","volume":"10","author":"Jaeger","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.intimp.2023.110973_b0200","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/pcmr.12909","article-title":"Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response","volume":"33","author":"Loo","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2023.110973_b0205","article-title":"Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110973_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6234","article-title":"A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations","author":"Sun","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2023.110973_b0215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.110973_b0220","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-022-30881-9","article-title":"Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation","volume":"13","author":"Murphy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110973_b0225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","article-title":"Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties","volume":"62","author":"Ott","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2023.110973_b0230","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/1078-0432.CCR-09-0399","article-title":"Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma","volume":"15","author":"Zhao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110973_b0235","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1038\/s41598-017-12208-7","article-title":"Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response","volume":"7","author":"Soukup","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110973_b0240","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"key":"10.1016\/j.intimp.2023.110973_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071452","article-title":"Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians","volume":"10","author":"Borkowska","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2023.110973_b0250","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1245\/s10434-022-11478-4","article-title":"Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort","volume":"29","author":"Straker","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.intimp.2023.110973_b0255","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/his.13527","article-title":"PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients","volume":"73","author":"Ren","year":"2018","journal-title":"Histopathology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923012985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923012985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:10:44Z","timestamp":1761588644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923012985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":51,"alternative-id":["S1567576923012985"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110973","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110973"}}